RASCASE 1.5MG INJECTION

RASCASE 1.5MG INJECTION is used to prevent or treat hyperuricemia (high levels of uric acid in the blood) in patients who are undergoing cancer chemotherapy for leukemia, lymphoma, and solid tumor malignancies.

Yes, it is an important supportive therapy for patients undergoing chemotherapy to reduce the risk of complications associated with high levels of uric acid in the blood.

RASCASE 1.5MG INJECTION are not indicated for those who have already developed acute gout or hyperuricemia due to conditions other than cancer chemotherapy.

It is advised to avoid certain medications, such as allopurinol, which is used to lower uric acid levels. Using allopurinol with RASCASE 1.5MG INJECTION together can reduce the effectiveness of rasburicase.

RASCASE 1.5MG INJECTION works by converting uric acid into allantoin, a more soluble compound that can be easily excreted by the kidneys. This reduces the levels of uric acid in the blood and prevents the development of hyperuricemia.

Yes, it is often used prophylactically in individuals who are at high risk for TLS due to their cancer chemotherapy.

Yes, RASCASE 1.5MG INJECTION can interact with certain medicines. It is important to inform your doctor about all medications you are taking, especially allopurinol, as combining them can reduce the effectiveness of RASCASE 1.5MG INJECTION.

You should avoid foods high in purines like red meat, organ meats, and some seafood. Avoid driving or operating heavy machinery if you feel tired or weak. Also, avoid fasting, rapid weight loss, and stress. Stay well-hydrated by drinking plenty of fluids, especially water. It is also advised to avoid smoking or using tobacco products.

The active ingredient in RASCASE 1.5MG INJECTION is Rasburicase.

RASCASE 1.5MG INJECTION is given during cancer chemotherapy to prevent or treat high levels of uric acid in the blood (hyperuricemia), which can occur due to the breakdown of cancer cells.

Yes, RASCASE 1.5MG INJECTION is often used to help prevent or manage Tumor Lysis Syndrome (TLS), a condition that can occur in cancer patients undergoing chemotherapy where many cancer cells break down rapidly, releasing harmful substances like uric acid into the blood.